Construction of Smart DNA-Based Drug Delivery Systems for Cancer Therapy.
Congcong LiMengzhen WangPei-Feng LiJunyue ShengQinrui FuPublished in: Small (Weinheim an der Bergstrasse, Germany) (2024)
Due to the disadvantages of poor targeting, slow action, and low effectiveness of current commonly used cancer treatments, including surgery, chemotherapy, and radiotherapy, researchers have turned to DNA as a biomaterial for constructing drug delivery nanocarriers. DNA is favored for its biocompatibility and programmability. In order to overcome the limitations associated with traditional drug delivery systems (DDSs), researchers have developed smart-responsive DNA DDSs that can control drug release in response to specific physical or chemical stimuli at targeted sites. In this review, a summary of multiple targeted ligand structures is provided, various shapes of stable DNA nanomaterials, and different stimuli-responsive drug release strategies in DNA DDSs. Specifically, targeted cell recognition, in vivo stable transport, and controlled drug release of smart DDSs are focused. Finally, the further development prospects and challenges of clinical application of DNA nanomaterials in the field of smart drug delivery are discussed. The objective of this review is to enhance researchers' comprehension regarding the potential application of DNA nanomaterials in precision drug delivery, with the aim of expediting the clinical implementation of intelligent DDSs.
Keyphrases
- drug delivery
- cancer therapy
- drug release
- circulating tumor
- cell free
- single molecule
- randomized controlled trial
- nucleic acid
- healthcare
- primary care
- physical activity
- circulating tumor cells
- minimally invasive
- systematic review
- mental health
- stem cells
- high resolution
- bone marrow
- mass spectrometry
- risk assessment
- single cell
- mesenchymal stem cells
- acute coronary syndrome
- rectal cancer
- tissue engineering